$NWBO Here is the two CHM Minutes where Licensing and Brain Cancer mentioned. Whether this the first and second RFI is my main focus point. If the second RFI was indeed 11/28/2026 NWBO had 3 months to respond at this time of clock stop, then MHRA has up 210 days to make the final decision on approval. (Total of 300 days, 3 months 210) If necessary a third RFI would be sent to resolve any final minor outstanding issues and switch off the clock again up to 3 months plus 210 days or 300 days max for approval decision. If we did get an RFI Nov 28th of 2025, max decision with no 3rd RFI would be 09/24/2026. 90 days ended FEB 25th, 2026. So MHRA is in decision mode of either 3rd RFI or a final decision by end of September at the latest is my estimation assuming second RFI November 28th, 2025. I have question in now about time frame in general to MHRA, I am not mentioning DCVAX by name, I want to know how an application can go 869 days without a decision based on their on guidance here. gov.uk/guidance/national-ass…

In the summer of 2010, David Fajgenbaum was everything a young man could hope to be. He had been a Division I college quarterback. He spoke multiple languages. He was in his third year at one of America's top medical schools, the University of Pennsylvania. He had his whole life mapped out in front of him. Then his body turned on him. Almost overnight, his organs began failing. His lymph nodes swelled. He was exhausted beyond anything he had ever felt. Within days, he was rushed to the emergency room. Weeks of testing followed. Finally, doctors gave it a name: Castleman disease — a rare and catastrophic condition where the immune system attacks the body's own organs. There was no cure. There was barely a treatment. A priest came to his hospital room and read his last rites. David said goodbye to his family. Then, somehow, an aggressive round of chemotherapy pulled him back from the edge. But it didn't hold. Within three years, he collapsed again. And again. And again. Five times in total, he came to the edge of death. Five times, chemotherapy bought him a little more time. After the fifth collapse, his doctors sat with him and said the words no patient wants to hear: his body had received the maximum amount of chemotherapy a human being can survive. If he relapsed again, there would be nothing left to give him. He would die. Most people, hearing that, would have spent whatever time remained saying goodbye. David Fajgenbaum picked up a medical journal. From his hospital bed, between treatments, he began doing something no patient had ever done before — systematically studying his own disease with the full knowledge of a trained physician. He analyzed thousands of pages of his own medical records. He tested his own blood samples, looking for patterns invisible to everyone else because no one else had both the data and the desperate motivation to find them. And he found something. In his lymph node samples, a specific protein signaling pathway called mTOR was firing at abnormally high levels — essentially sending the immune system into a frenzy that destroyed his own organs. It was a clue no one had spotted because no one had looked in quite that way before. Then he searched for something that could stop it. He found it in an unlikely place: a medication called sirolimus, already approved and available, commonly used to prevent organ rejection after kidney transplants. No one had ever tried it for Castleman disease. But on paper, its mechanism was a near-perfect match for what David had found in his own blood. Under his doctor's supervision, he began taking it. Within days, his symptoms vanished. Not improved. Vanished. The man doctors had given up on walked out of the hospital. He finished medical school. He married his girlfriend Caitlin. He became a father. He became one of the youngest faculty members ever to receive tenure at Penn Medicine. And then he turned around to face everyone still waiting in the dark. He founded the Castleman Disease Collaborative Network, building the first global research effort for a disease that had none. He launched Every Cure — an organization that uses artificial intelligence to search all existing approved drugs for hidden matches with diseases that currently have no treatment. The idea is simple and revolutionary: there are over 1,500 approved drugs in the world and over 7,000 diseases with no treatment. The cures may already exist. They just haven't been matched yet. Over 15 years, Fajgenbaum and his partners have helped advance 28 repurposed drugs — 14 directly led by him. MedicalXpress A priest once came to read him his last rites. Today, David Fajgenbaum has authored over 100 scientific papers, appeared on TIME's list of the world's most influential people in health, and continues to take his small sirolimus tablet every single morning the pill he found himself, in the darkest room of his life, when no one else was looking. He didn't wait to be saved.